Royalty Pharma

gems jewels crown diamonds rocks
Biotech

Royalty bestows Zenas with $300M for autoimmune approval push

Royalty is paying Zenas $75 million upfront, with similar payments coming if obexelimab succeeds in phase 3 and secures FDA approval.
Darren Incorvaia Sep 2, 2025 11:07am
increase

Royalty signs off $2B to bankroll Revolution's RAS cancer drug

Jun 24, 2025 9:00am
crown royalty king queen win

Biogen taps Royalty for $250M to fund phase 3 lupus program

Feb 12, 2025 8:10am
unhappy angry mad sad alone smile emotions

Investors say 'no bueno' to Cytokinetics' complex Royalty deal

May 23, 2024 10:36am
one white and yellow capsule farther ahead than four other same-colored blue capsules

Karuna's new schizophrenia drug reaches FDA's desk

Sep 28, 2023 11:12am
money bills fundraise

Royalty swoops in with $100M upfront for slice of Karuna's KarXT

Mar 23, 2023 9:45am